Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | PREP | P48147 | 2/20 | 0.46 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.46 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.46 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.46 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.46 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.46 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.45 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.45 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27829651 | 0.84 | SMN1; SMN2 (0.47) | SMN1; SMN2NPC1RAB9AHTR2CACE2 | |
| SCHEMBL2206501 | 0.84 | SMN1; SMN2 (0.47) | SMN1; SMN2NPC1RAB9AHTR2CACE2 | |
| SCHEMBL2208901 | 0.83 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9AHTR2CACE2 | |
| SCHEMBL2210145 | 0.83 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9AHTR2CACE2 | |
| SCHEMBL12433111 | 0.83 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9AHTR2CACE2 | |
| SCHEMBL2210787 | 0.82 | SMN1; SMN2 (0.45) | SMN1; SMN2NPC1RAB9AHTR2CCYP2C19 | |
| SCHEMBL1643460 | 0.81 | HTR2C (0.51) | SMN1; SMN2NPC1RAB9AHTR2CCYP2C19 | |
| SCHEMBL2388729 | 0.79 | SMN1; SMN2 (0.47) | SMN1; SMN2NPC1RAB9AHTR2CACE2 | |
| SCHEMBL21241492 | 0.79 | HTR2C (0.52) | SMN1; SMN2NPC1RAB9AHTR2CCYP2C19 | |
| SCHEMBL29997810 | 0.79 | PSEN1 (0.50) | SMN1; SMN2NPC1RAB9AHTR2CACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1912662-B1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-08-21 | — | — | EP | disclosed |
| EP-1912662-B1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-08-21 | — | — | EP | disclosed |
| US-7982053-B2 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2011-07-19 | — | — | US | disclosed |
| US-7982053-B2 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2011-07-19 | — | — | US | disclosed |
| US-7982053-B2 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2011-07-19 | — | — | US | disclosed |
| US-20090239866-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-24 | — | — | US | disclosed |
| US-20090239866-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-24 | — | — | US | disclosed |
| US-20090239866-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-24 | — | — | US | disclosed |
| EP-1912662-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SmithKline Beecham Corporation (US) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007016364-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007016364-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239866-A1 | PEPTIDE DEFORMYLASE INHIBITORS | PDF, PEPD, DPEP1 | SMN1; SMN2 2654/4885NPC1 1328/4885RAB9A 2101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.